

13 January 2026

Enlitic Completes Technical Validation of Ensign Platform

Enlitic, Inc. (ASX: ENL) (Enlitic) has completed a technical validation of its Ensign medical imaging data standardisation platform on Oracle Cloud Infrastructure (OCI), utilising AMD EPYC™ processors.

The validation was conducted to confirm that Ensign operates reliably, consistently, and at scale within a modern cloud environment suitable for varying clinical, operational, and research workflows.

Summary of Validation Activities and Outcomes

Testing was performed using anonymised medical imaging datasets representative of real-world healthcare environments, covering a range of anatomical regions and clinical contexts.

The validation assessed Ensign's ability to process varying data volumes across multiple system configurations, reflecting the operational conditions encountered by hospitals, radiology providers and research organisations.

The validation activities confirmed:

- Correct execution of medical imaging data standardisation and normalisation functions
- Stable and consistent system performance aligned with results achieved on prior infrastructure
- Reliable operation within defined system specifications
- Successful integration with OCI storage and managed database services

Customer and Partner Relevance

The validation activities demonstrated that Ensign can be deployed on OCI with AMD EPYC™ processors while maintaining functional integrity and performance consistency.

This provides healthcare customers with an additional validated infrastructure option for managing and standardising large-scale medical imaging datasets in secure cloud environments.

"Our work with AMD and Oracle has validated that Ensign performs as intended on a modern, scalable cloud platform," said **Michael Sistenich, CEO of Enlitic**. "This gives our

customers confidence that they can deploy Ensign in cloud environments that meet their performance, security, and scalability requirements.”

“The healthcare industry continues to adopt high-performance computing to address complex data challenges,” said **Tony Nunes, Senior Manager, Healthcare & Life Sciences, AMD Server Business Unit**. “This collaboration with Enlitic demonstrates how AMD EPYC processors can support demanding medical imaging and AI-enabled workloads in cloud environments.”

“OCI delivers a secure and high-performance cloud platform for healthcare and life sciences organisations,” said **Dan Spellman, Vice President, AI and OCI, Healthcare & Life Sciences, Oracle**. “Enlitic’s validation of Ensign on OCI highlights how cloud infrastructure can support reliable, large-scale healthcare data operations.”

This announcement has been authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:

invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.